Successful treatment with bortezomib for refractory fever associated with myelodysplastic syndrome with underlying lymphoplasmacytic lymphoma

Yotaro Motomura; Yoshihiro Umezawa; Tomoyuki Arimatsu; Keigo Okada; Osamu Miura; Takashi Kumagai

doi:10.1002/ccr3.5372

Clinical Case Reports (Feb 2022)

Successful treatment with bortezomib for refractory fever associated with myelodysplastic syndrome with underlying lymphoplasmacytic lymphoma

Yotaro Motomura,
Yoshihiro Umezawa,
Tomoyuki Arimatsu,
Keigo Okada,
Osamu Miura,
Takashi Kumagai

Affiliations

Yotaro Motomura: Department of Hematology Ome Municipal General Hospital Tokyo Japan
Yoshihiro Umezawa: Department of Hematology Tokyo Medical and Dental University Tokyo Japan
Tomoyuki Arimatsu: Department of Hematology Ome Municipal General Hospital Tokyo Japan
Keigo Okada: Department of Hematology Ome Municipal General Hospital Tokyo Japan
Osamu Miura: Department of Hematology Tokyo Medical and Dental University Tokyo Japan
Takashi Kumagai: Department of Hematology Ome Municipal General Hospital Tokyo Japan

DOI: https://doi.org/10.1002/ccr3.5372
Journal volume & issue: Vol. 10, no. 2
pp. n/a – n/a

Abstract

Read online

Abstract We report a case of fever of unknown origin in a patient with MDS associated with IgM‐MGUS. The patient was positive for MYD88 mutation, and chemotherapy for LPL/WM improved the fever. Analysis of MYD88 and the effect of chemotherapy on LPL/WM finally revealed the latent LPL/WM in this case.

Published in Clinical Case Reports

ISSN: 2050-0904 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Medicine (General)
Website: http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2050-0904

About the journal

Abstract

Keywords